Abstract
Purchase PDF (133 K)
E-mail Article
Add to my Quick Links
Cited By in Scopus (1)
Purchase PDF (739 K)
doi:10.1016/j.ijpharm.2006.11.011 
Copyright © 2006 Elsevier B.V. All rights reserved.
Pharmaceutical Nanotechnology
The effect of monomers on the formulation of polymeric nanocapsules based on polyureas and polyamides
Received 23 May 2006;
References and further reading may be available for this article. To view references and further reading you must purchase this article.
Abstract
Formulation of nanocapsules based on polyureas and polyamides have been tested using a patented process. This method based on polycondensation reaction of two complementary monomers and spontaneous formation of oil in water emulsion, is an alternative concept to the known technique based on the same type of reaction used for the formulation of microcapsules, and in which the lipophilic monomer was emulsified in the organic phase before the formation of the polymeric membrane. Nanocapsules can be prepared from different monomers. Wall based on cross-linked polymer contributes to the stability of nanocapsules during and after formulation. The permeability of the polymeric wall is related to its crystallinity and contributes to the growth of nanocapsule membrane by the diffusion of the hydrophilic monomers to get stable colloidal suspensions.
Keywords: Nanocapsules; Spontaneous emulsification; Interfacial polycondensation; Polymers
Article Outline
- 1. Introduction
- 2. Materials and methods
- 3. Results and discussion
- 3.1. Polymeric nanocapsules based on polyamides
- 3.1.1. Formulation using phtaloylchloride “PTC” as lipophilic monomer and ethylenediamine “EDA”, 1,6-hexamethylenediamine “HMDA” or diethylenetriamine “DETA” as hydrophilic monomers
- 3.1.2. Formulation using sebacoyl chloride “SC” as lipophilic monomer and ethylenediamine “EDA”, 1,6-hexamethylenediamine “HMDA” or diethylenetriamine “DETA” hydrophilic monomers
- 3.2. Polymeric nanocapsules based on polyureas
- 3.2.1. Formulation using 2,4-tolyenediisocyanate “TDI” as lipophilic monomer and ethylenediamine “EDA”, 1,6-hexamethylenediamine “HMDA” or diethylenetriamine “DETA” as hydrophilic monomers
- 3.2.2. Formulation using hexamethyle-1,6 diisocyanate “HMDI” as lipophilic monomer and ethylenediamine “EDA”, 1,6-hexamethylenediamine “HMDA” or diethylenetriamine “DETA” as hydrophilic monomers
- 4. Conclusion
- References
